Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

800

Participants

Timeline

Start Date

June 23, 2015

Primary Completion Date

April 25, 2019

Study Completion Date

March 31, 2026

Conditions
Bronchopulmonary DysplasiaChild DevelopmentNeonatal and Perinatal Conditions
Interventions
DIETARY_SUPPLEMENT

DHA-rich algal oil

Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.

COMBINATION_PRODUCT

Placebo

Mothers will receive a placebo capsule three times a day before meals from randomization (\<72 hours post-delivery) until the infant reaches 36 weeks PMA.

Trial Locations (16)

T2N 2T9

Foothills Medical Centre, Calgary

T5H 3V9

Royal Alexander Hospital, Edmonton

V3L 3W7

Royal Columbian Hospital, New Westminster

V6H 3V4

Children's and Women's Health Centre of British Columbia, Vancouver

V8R 1J8

Victoria General Hospital, Victoria

R2H 2A6

St Boniface General Hospital, Winnipeg

R3A 1R9

Health Sciences Centre, Winnipeg

B3K 6R8

IWK Health Centre, Halifax

K7L 2V7

Kingston Health Science Centre, Kingston

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

H3T 1C5

CHU Sainte-Justine, Montreal

H3T 1E2

Jewish General Centre, Montreal

H4A 3J1

McGill University Health Center, Glen Site, Montreal Children's Hospital, Montreal

G1V 4G2

CHU de Québec-Université Laval, Centre Mère Enfant Soleil du CHUL, Québec

J1H 5N4

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

S7N 0W8

Royal University Hospital, Saskatoon

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Laval University

OTHER

lead

CHU de Quebec-Universite Laval

OTHER